Partnership Agreement Between Mireca and Graybug Terminated

Mireca Medicines announced that the partnership agreement between Mireca and Graybug (now CalciMedica) has been terminated due to a shift in drug development focus of CalciMedica away from ocular diseases.

As part of the termination, all intellectual property rights that Mireca had previously sold to Graybug have been (re)assigned to Mireca, along with an additional patent application protecting select cyclic guanosine monophosphate (cGMP)-analogs in Graybug’s sustained-release drug delivery technology, according to a Mireca news release.

"Under the terms of this agreement, ownership of all formulation and release data for select cGMP-analogs in Graybug’s sustained-release drug delivery technologies, as protected in a new patent application, was also assigned to Mireca. Furthermore, an improved, patent protected cGMP-analog was selected as lead compound and a new, proprietary manufacturing process conforming to the standards of good-manufacturing practice (GMP) was developed. Various cGMP-analog salt forms produced with this new manufacturing process are now also owned by Mireca," Mireca stated in the news release. "After this fruitful period of external collaborative development with Graybug, Mireca will continue the development of the new lead compound and formulation combination, now designated as MM238, as internal lead product. The focus for MM238 drug development continues to be the treatment of inherited retinal diseases (IRDs), such as retinitis pigmentosa, Leber’s congenital amaurosis, and Stargardt’s disease."

“During the partnership with Graybug, some major advancements were achieved for Mireca’s cGMP-analogs on the path toward potential treatments for patients suffering from IRDs. It feels so good to be reunited with our value-added lead product MM238. It fills us with energy and confidence for its further development. We have increased our partnering and fundraising efforts to fully capitalize on the potential of our compounds in IRDs and other neurodegenerative diseases," said Barbara Brunnhuber, Chief Executive Officer of Mireca.